Multi-Omics Reveals Tumor-Draining Lymph Nodes as Critical Hubs for Cancer Immunotherapy
核心洞察
Tumor-draining lymph nodes (搜索) (TDLNs) serve dual roles as both immune activation centers and metastatic sites, with multi-omics technologies revealing their complex cellular interactions and microenvironmental changes during cancer progression.
Research demonstrates that TDLNs undergo dynamic remodeling during immunotherapy, radiotherapy, chemotherapy, and targeted therapy, with stem-like CD8+ T cells (搜索) (Tpex) in non-metastatic lymph nodes showing superior responses to immune checkpoint inhibitors (搜索).
A new framework called Lymph Node Multi-modal Protective Research (LNMPR) is proposed, emphasizing selective lymph node preservation, comprehensive multi-omics profiling, and clinical translation to optimize cancer treatment strategies.
Multi-Omics Reveals Tumor-Draining Lymph Nodes as Critical Hubs for Cancer Immunotherapy
Recent advances in multi-omics technologies are revolutionizing our understanding of tumor-draining lymph nodes (搜索) (TDLNs), revealing them as sophisticated immune hubs rather than mere "metastatic garbage dumps." Two comprehensive reviews highlight how these secondary immune organs orchestrate both anti-tumor immunity and cancer immune evasion, fundamentally changing therapeutic approaches.
From Surgical Targets to Immune Treasures
The paradigm surrounding lymph nodes in cancer treatment has undergone a dramatic shift. Historically, radical lymph node dissection was standard practice, based on the belief that lymph nodes served as stepping stones for metastatic spread. However, genomic analyses of colorectal and breast cancers reveal that distant metastases often arise independently of lymph node clones, challenging the necessity of routine dissection.
Clinical evidence supports this paradigm shift. Axillary dissection in breast cancer (搜索) reduces peripheral CD8+ T cells (搜索) by 37%, impairing immune surveillance. Sentinel lymph node biopsy has significantly reduced postoperative lymphedema incidence from 35-40% to 5-7% while maintaining equivalent tumor control, demonstrating the therapeutic value of lymph node preservation.
Multi-Omics Unveils Complex Immune Networks
Single-cell RNA sequencing and spatial transcriptomics have revealed TDLNs as "decision-making centers" for systemic immune regulation. In head and neck cancer (搜索) patients, precursor exhausted T cells (Tpex) with stem cell characteristics are positioned near dendritic cells (搜索) in uninvolved lymph nodes. These cells can differentiate into intermediate exhausted T cells post anti-PD-L1 (搜索) immunotherapy and infiltrate tumors.
Spatial proteomic analysis of breast cancer (搜索) primary tumors and paired lymph node metastases reveals survival-associated cellular phenotypes that outperform traditional clinical classification criteria such as TNM staging or molecular subtypes.
Dynamic Responses Across Treatment Modalities
Immunotherapy Mechanisms
TDLNs serve as critical sites where immune checkpoint inhibitors (搜索) (ICIs) exert their effects. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within tumors. Tpex cells in TDLNs are highly responsive to ICIs, with robust T cell responses seen in non-metastatic lymph nodes being impaired in metastatic nodes.
Research demonstrates that removing TDLNs during neoadjuvant treatment significantly inhibits the expansion of tumor-specific memory T cells, almost completely abolishing the efficacy of PD-L1 (搜索) blockade. This indicates TDLNs play an irreplaceable role as activation hubs in early treatment responses.
Radiotherapy and Chemotherapy Effects
Radiotherapy not only targets tumor cells directly but also remodels the immune microenvironment of TDLNs. Neoadjuvant concurrent chemoradiotherapy directed solely at primary tumors while preserving lymph nodes shows that preserved TDLNs exhibit gene expression profiles associated with better pathological responses.
Chemotherapy exerts paradoxical effects on TDLN-resident immune cells. While certain agents induce lymphocyte depletion, specific chemotherapeutics like anthracyclines (搜索) can promote immunogenic cell death, releasing damage-associated molecular patterns that activate dendritic cells (搜索) in TDLNs.
Neural Regulation Adds Complexity
Recent discoveries reveal that lymph nodes are densely innervated by both sympathetic and sensory nerve fibers. Sympathetic activation impairs anti-tumor immune responses within lymph nodes by reducing T cell, B cell, and antigen-presenting cell motility. Sensory nerves modulate antigen flow and retention, with nociceptor activation restricting antigen transit between lymph nodes.
This neural innervation creates potential tripartite tumor-neuro-immune interactions within TDLNs. Tumor-derived factors may cause remodeling and stimulation of lymph node-innervating fibers, while elevated solid stress in TDLNs could activate pressure-sensitive sensory nerves, potentially contributing to early immunosuppression.
The LNMPR Framework for Clinical Translation
To harness the dual nature of TDLNs, researchers propose the Lymph Node Multi-modal Protective Research (LNMPR) framework, emphasizing three pillars:
LN Preservation: Selective dissection strategies minimize surgical damage to immune architecture while ensuring proper tissue storage for analysis.
Multimodal Profiling: Combining fresh and FFPE samples enables comprehensive dissection of lymph node biology through single-cell transcriptomics, spatial omics, and proteomics.
Clinical Translation: Correlating lymph node immune maps with treatment responses enables prognostic stratification and personalized intervention strategies.
Clinical Implications and Future Directions
The evidence strongly supports preserving non-metastatic TDLNs to boost systemic immunity while developing strategies to reprogram metastatic lymph nodes. Neoadjuvant immunotherapy has demonstrated superior efficacy compared to adjuvant approaches, likely due to intact TDLN function during initial treatment.
Future therapeutic strategies should move from "removal" to "preserve and optimize," exploring how to fully harness the anti-tumor immune potential of TDLNs. This includes targeted delivery of immune checkpoint inhibitors (搜索) to lymph nodes, which has shown enhanced therapeutic efficacy in preclinical models.
The integration of multi-omics approaches with clinical outcomes promises to advance precision oncology, transforming TDLNs from surgical targets into critical allies for enhancing anti-tumor immunity. As spatial technologies and immunotherapy continue evolving, the LNMPR framework may catalyze a paradigm shift toward immune-ecosystem preservation and optimization.